&w=3840&q=100)
PL Capital bets on domestic sectors, sees 6.5% Nifty growth in 12 months
Indian markets have shown a lot of resilience in the past few months despite big events, and seem to have learnt to live with global volatility and adverse geopolitical news flows, the brokerage said in an India Strategy report.
On the domestic front, it said that the first quarter (Q1-FY26) has seen the front-end of government capital expenditure with a growth of 61 per cent and 39 per cent in April and May. "There is a momentum in ordering and a significant pick up in defence expenditure." Further monetary easing by the Reserve Bank of India (RBI) will help improve the liquidity in the system and improve credit growth, it said.
Given that, all eyes rest on the revival of consumption demand, analysts said, favouring stocks in these sectors. Additionally, normal monsoons, multi-year low food inflation, and benefits of tax cuts in the FY26 budget could also boost domestic demand. India Inc. in Q1 has shown a mixed trend, but the upcoming festival season and spatial distribution of monsoons hold the key to broad-based demand revival, PL Capital noted.
The brokerage set a 12-month target of 26,889 (6.7 per cent upside from Wednesday' close), up from 25,521 earlier, adding that sectors such as pharmaceuticals, select consumer staples, banks, capital goods, defence, and power are expected to outperform in the near term. In a bull case scenario, the Nifty is expected to move up to 28,957 levels.
Earnings outlook
PL Capital notes that the earnings outlook remains uncertain, with its Nifty EPS estimates for FY26 and FY27 cut by 7.3 per cent and 6.15 per cent, respectively. Consensus cuts are even steeper at 8.9 and 7.5 per cent, it noted. Despite this, the Nifty has risen just 0.8 per cent since the EPS downgrade began in October 2024.
Sectors like building materials, durables, pharma, and travel are expected to report margin declines, while cement, metals, oil & gas, EMS, and telecom should see sharp expansions, the note said.
Urban demand remains sluggish, though rural consumption is steady. Marriage season demand has aided jewellery and two-wheeler sales, while early rains have hit durables. Capital goods and defence are buoyed by strong government capex. PL Capital said.
Banks face credit pressure, but rate and CRR cuts may aid margins. EMS, AMCs, and commodity plays will lead profit growth, while IT, consumer, pharma, and travel sectors will post modest gains, according to PL Capital.
High-conviction stock picks
PL Capital has removed Max Healthcare, Britannia, Mahindra and Mahindra, Sun Pharma, Rainbow Hospitals, Chalet Hotels, and Eris Lifesciences from its list of high-conviction picks.
While the brokerage remains structurally positive on most of these names, it believes the current valuations offer little room for further gains in the short term. In their place, PL Capital has added Apollo Hospitals, Lupin Laboratories, and Samhi Hotels to its conviction list.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New Indian Express
17 minutes ago
- New Indian Express
PM Modi to visit UK and Maldives, key trade pact and diplomatic reset likely
NEW DELHI: Prime Minister Narendra Modi will travel to the United Kingdom and the Maldives from July 23 to 26 in a high-stakes diplomatic tour focused on advancing bilateral ties and formalising a major free trade agreement (FTA) with Britain. 'During the visit, Prime Minister Modi will hold wide-ranging discussions with Prime Minister Starmer on the entire gamut of India-UK bilateral relations. They will also exchange views on issues of regional and global importance,' the External Affairs Ministry said in a statement. The centrepiece of the visit on July 23 and 24 is expected to be the formal signing of the India-UK FTA, finalised in May and currently undergoing legal scrubbing by both sides. The landmark deal aims to double bilateral trade, which is currently valued at $60 billion by 2030. It is expected to boost Indian exports of textiles, leather and engineering goods, while slashing tariffs on British whisky, automobiles, and medical devices.


Time of India
an hour ago
- Time of India
Indian millers, exporters optimistic as Bangladesh plans to import 9 lakh tonne rice: Stakeholders
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Indian rice millers and exporters are upbeat about Bangladesh's "plan to import 9 lakh tonnes of rice", anticipating a boost in demand and better prices for the cereal, stakeholders said on India accounting for 46 per cent of global rice exports, the country is expected to "emerge as the primary beneficiary of the move for its proximity, availability, and competitive pricing", they said."Of the total import plan, 4 lakh tonnes will be procured directly by the Bangladesh government through international tenders, while another 5 lakh tonnes will be imported by private traders of the neighbouring country. The decision comes earlier than usual, amid fear of crop loss due to heavy rain that could impact Bangladesh's Amon paddy currently being sown," Ricevilla Foods CEO Suraj Agarwal told Baba Bakreswar Rice Mill Director Rahul Agarwal said the rice industry in the country, especially in Bengal, is well-positioned to benefit from the proposed plan by the Bangladesh authorities, and he did not foresee any diplomatic hurdle amid India's curbs on the import of garments and jute through the Petrapole border."At least 30-40 per cent of the private imports will likely be sourced from Bengal mills and traders. Bengal mills will also participate in the government tenders for 4 lakh tonnes. States like Bengal, Jharkhand, Andhra Pradesh, Odisha, and Bihar will benefit the most," he Indian rice varieties such as 'Swarna', 'Ratna', 'Miniket', and 'Sona Masoori' are expected to see price gains in both West Bengal and southern India amid the anticipated demand surge, he of 'Swarna Mansoori' parboiled rice, now at Rs 29 per kg (ex-mill), may rise to Rs 31-32, while 'Miniket' variety currently being sold at Rs 41-42, could touch Rs 45 per kg in the coming weeks, Suraj Agarwal early import plan reflects "precautionary steps ahead of possible floods during the Amon season", the stakeholders Bangladesh government has already procured 3.76 lakh tonnes of Boro paddy and 9.50 lakh tonnes of rice against a target of 14 lakh tonnes, with procurement set to conclude by mid-August, according to August, Bangladesh proposed to expand its food-friendly programme to 55 lakh families, providing 30 kg of rice per month at Tk 15 per kg during August, September, October, November, February, and March, the reports believe the development will further strengthen "India's position as Bangladesh's key rice supplier while firming up prices for low-to-medium rice varieties in the domestic market".Visakhapatnam and Paradip ports are major ones for rice exports.


Economic Times
an hour ago
- Economic Times
Anthem Biosciences IPO: What GMP signals ahead of listing on Monday
Anthem Biosciences is set to debut on the stock exchanges on Monday, July 21. In the unlisted market, its shares are trading at a premium of Rs 165–170, indicating a potential listing gain of around 29% over the IPO price of Rs 570 (upper band). ADVERTISEMENT While the grey market premium (GMP) reflects strong investor interest, it remains a speculative indicator and can change quickly before listing. The Rs 3,395 crore IPO was entirely an offer for sale (OFS) and closed on July 16. It witnessed robust demand, with an overall subscription of 67.42 times. The Qualified Institutional Buyers (QIB) segment was subscribed 192.80 times, Non-Institutional Investors (NII) 44.70 times, and the retail portion 5.98 times. The issue was priced in a band of Rs 540–570 per share, with a minimum lot size of 26 shares. The stock will list on both NSE and BSE. Founded in 2006, Anthem Biosciences operates in a niche segment of the pharma value chain, offering end-to-end drug discovery, development, and manufacturing services. It is among the few Indian CRDMOs with integrated capabilities across both small molecules (chemical-based) and large molecules (biologics).Its differentiated fee-for-service (FFS) model has enabled it to cater to small and mid-sized biotech firms globally, which constitute a large portion of its client base. Since its inception, the company has served over 675 clients and completed more than 8,000 projects. ADVERTISEMENT In FY25, Anthem reported strong financials, with an EBITDA margin of 36.8% and a Return on Net Worth (RoNW) of 20.8%. As of March 2025, the company's net worth stood at Rs 2,410 facilities are cGMP-compliant and approved by global regulatory bodies such as the USFDA, ANVISA, TGA, and PMDA. The company is currently expanding its fermentation and synthesis capacities to meet growing demand for complex biologics and specialty ingredients. ADVERTISEMENT JM Financial is the book-running lead manager of the Anthem Biosciences IPO, while Kfin Technologies is the registrar for the issue. (Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)